Search research articles
Contact Us
Filters
Showing results (511-520 of 630) with videos related to
Page
of 63
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2022
Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting
Sunita D Nasta, Mitchell E Hughes, Esin C Namoglu, et al.
Blood Advances
|
December 12, 2022
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
Shakthi T Bhaskar, Vivek G Patel, David L Porter, et al.
Journal of the American Chemical Society
|
September 8, 2021
Correction to "A Design Strategy for Intrinsically Stretchable High-Performance Polymer Semiconductors: Incorporating Conjugated Rigid Fused-Rings with Bulky Side Groups"
Deyu Liu, Jaewan Mun, Gan Chen, et al.
Clinical and Translational Radiation Oncology
|
January 31, 2023
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
Nikhil Yegya-Raman, Christopher M Wright, Michael J LaRiviere, et al.
Clinical Transplantation
|
September 9, 2005
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder
Donald E Tsai, Nicole A Aqui, John E Tomaszewski, et al.
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2003
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Robert M Sharkey, Arnold Brenner, Jack Burton, et al.
Blood
|
December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Molecular Cancer Research : MCR
|
March 14, 2019
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells
Seung-Cheol Lee, Alexander A Shestov, Lili Guo, et al.
Leukemia
|
February 17, 2026
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma
Daniel J Landsburg, Nancy Musoke, Caren Gentile, et al.
Page
of 63
Search research articles
Search
Showing results (511-520 of 630) with videos related to
Sort By:
Page
of 63
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2022
Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting
Sunita D Nasta, Mitchell E Hughes, Esin C Namoglu, et al.
Blood Advances
|
December 12, 2022
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
Shakthi T Bhaskar, Vivek G Patel, David L Porter, et al.
Journal of the American Chemical Society
|
September 8, 2021
Correction to "A Design Strategy for Intrinsically Stretchable High-Performance Polymer Semiconductors: Incorporating Conjugated Rigid Fused-Rings with Bulky Side Groups"
Deyu Liu, Jaewan Mun, Gan Chen, et al.
Clinical and Translational Radiation Oncology
|
January 31, 2023
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
Nikhil Yegya-Raman, Christopher M Wright, Michael J LaRiviere, et al.
Clinical Transplantation
|
September 9, 2005
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder
Donald E Tsai, Nicole A Aqui, John E Tomaszewski, et al.
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 9, 2003
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Robert M Sharkey, Arnold Brenner, Jack Burton, et al.
Blood
|
December 4, 2023
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, et al.
Molecular Cancer Research : MCR
|
March 14, 2019
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells
Seung-Cheol Lee, Alexander A Shestov, Lili Guo, et al.
Leukemia
|
February 17, 2026
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma
Daniel J Landsburg, Nancy Musoke, Caren Gentile, et al.
Page
of 63